KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt Ratio (2019 - 2025)

Historic Debt Ratio for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 0.46.

  • Royalty Pharma's Debt Ratio rose 966.08% to 0.46 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46, marking a year-over-year increase of 966.08%. This contributed to the annual value of 0.42 for FY2024, which is 1154.19% up from last year.
  • Latest data reveals that Royalty Pharma reported Debt Ratio of 0.46 as of Q3 2025, which was up 966.08% from 0.44 recorded in Q2 2025.
  • Royalty Pharma's 5-year Debt Ratio high stood at 0.46 for Q3 2025, and its period low was 0.36 during Q2 2021.
  • Over the past 5 years, Royalty Pharma's median Debt Ratio value was 0.42 (recorded in 2022), while the average stood at 0.41.
  • Its Debt Ratio has fluctuated over the past 5 years, first crashed by 1151.42% in 2023, then skyrocketed by 1366.52% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Debt Ratio stood at 0.41 in 2021, then increased by 2.91% to 0.42 in 2022, then decreased by 11.51% to 0.37 in 2023, then grew by 11.54% to 0.42 in 2024, then increased by 10.68% to 0.46 in 2025.
  • Its Debt Ratio was 0.46 in Q3 2025, compared to 0.44 in Q2 2025 and 0.43 in Q1 2025.